185 related articles for article (PubMed ID: 26782967)
1. Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
Kim EY; Cho EN; Park HS; Kim A; Hong JY; Lim S; Youn JP; Hwang SY; Chang YS
BMC Cancer; 2016 Jan; 16():27. PubMed ID: 26782967
[TBL] [Abstract][Full Text] [Related]
2. Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naïve advanced non-squamous non-small cell lung cancer patients.
Xie F; Zhang Y; Mao X; Zheng X; Han-Zhang H; Ye J; Zhao R; Zhang X; Sun J
Lung Cancer; 2018 Jul; 121():54-60. PubMed ID: 29858028
[TBL] [Abstract][Full Text] [Related]
3. BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis.
Cho EN; Kim EY; Jung JY; Kim A; Oh IJ; Kim YC; Chang YS
Lung Cancer; 2015 Oct; 90(1):106-10. PubMed ID: 26271547
[TBL] [Abstract][Full Text] [Related]
4. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.
Park S; Holmes-Tisch AJ; Cho EY; Shim YM; Kim J; Kim HS; Lee J; Park YH; Ahn JS; Park K; Jänne PA; Ahn MJ
J Thorac Oncol; 2009 Jul; 4(7):809-15. PubMed ID: 19487967
[TBL] [Abstract][Full Text] [Related]
5. Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2.
Legras A; Roussel H; Mangiameli G; Arame A; Grand B; Pricopi C; Badia A; Gibault L; Badoual C; Fabre E; Laurent-Puig P; Blons H; Le Pimpec-Barthes F
Pathol Oncol Res; 2019 Jan; 25(1):319-325. PubMed ID: 29110262
[TBL] [Abstract][Full Text] [Related]
6. Triple Gene Analysis Using Samples Obtained by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration.
Lee K; Um SW; Jeong BH; Yang JW; Choi YL; Han J; Kim H; Kwon OJ
Intern Med; 2016; 55(21):3105-3111. PubMed ID: 27803402
[TBL] [Abstract][Full Text] [Related]
7. Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
Nakajima T; Yasufuku K; Nakagawara A; Kimura H; Yoshino I
Chest; 2011 Nov; 140(5):1319-1324. PubMed ID: 21527506
[TBL] [Abstract][Full Text] [Related]
8. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
9. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer.
Furuki H; Yamada T; Takahashi G; Iwai T; Koizumi M; Shinji S; Yokoyama Y; Takeda K; Taniai N; Uchida E
Eur J Surg Oncol; 2018 Jul; 44(7):975-982. PubMed ID: 29452859
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
12. Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
Bonanno L; Calabrese F; Nardo G; Calistri D; Tebaldi M; Tedaldi G; Polo V; Vuljan S; Favaretto A; Conte P; Amadori A; Rea F; Indraccolo S
Lung Cancer; 2016 Jun; 96():52-5. PubMed ID: 27133750
[TBL] [Abstract][Full Text] [Related]
13. Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma.
Ito M; Miyata Y; Hirano S; Kimura S; Irisuna F; Ikeda K; Kushitani K; Kishi N; Tsutani Y; Takeshima Y; Okada M
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2325-2333. PubMed ID: 31317326
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer.
Alsdorf WH; Clauditz TS; Hoenig T; Quaas A; Sirma H; Koenig AM; Izbicki J; Sauter G; Marx AH; Grob TJ
Exp Mol Pathol; 2013 Feb; 94(1):155-9. PubMed ID: 23022742
[TBL] [Abstract][Full Text] [Related]
15. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
18. Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach.
Lorber T; Andor N; Dietsche T; Perrina V; Juskevicius D; Pereira K; Greer SU; Krause A; Müller DC; Savic Prince S; Lardinois D; Barrett MT; Ruiz C; Bubendorf L
J Pathol; 2019 Feb; 247(2):199-213. PubMed ID: 30350422
[TBL] [Abstract][Full Text] [Related]
19. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
